Questions about this study?
The HopeStage team will email you.
Not recruitingEUCTR 2008-000908-91
A randomised, 6-week, multicentre, open-label, rater-blinded parallelgroup study comparing Quetiapine extended release monotherapy and augmentation with Lithium augmentation in patients with Treatm...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Austria · Belgium and 8 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 600
- Sponsor
- AstraZeneca AB
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United Kingdom, Belgium, Austria, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2008-000908-91
- Official title
Show the full official title
A randomised, 6-week, multicentre, open-label, rater-blinded parallelgroup study comparing Quetiapine extended release monotherapy and augmentation with Lithium augmentation in patients with Treatm...
Recruitment & locations
Not recruitingAustria · Belgium · Bulgaria
7 more locations
- Denmark
- Germany
- Hungary
- Italy
- Portugal
- Slovakia
- United Kingdom
Registry details
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca AB.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ...
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i...